Retatrutide + Cagrilintide
aka Reta + Cagri · Triple-agonist + amylin blend
Mechanism
Pre-mixed metabolic blend combining retatrutide, an investigational GIP/GLP-1/glucagon triple receptor agonist, with cagrilintide, a long-acting amylin analog, both targeting appetite, satiety and energy balance for weight loss. Neither component is FDA-approved: retatrutide is in Eli Lilly's Phase 3 TRIUMPH program (NDA anticipated late 2026, approval not expected before 2027), and cagrilintide is investigational, studied mainly in Novo Nordisk's CagriSema combination. This specific blend is not an approved product and has no published controlled human efficacy or safety data; any rationale is inferred from the separate development-stage compounds, and combination-specific human data is lacking.
Studied uses
- Marketed (research only) for weight loss and obesity-related metabolic support
- Claimed appetite suppression and improved satiety
- Investigational/research interest in additive metabolic effects of incretin + amylin pathways
Identification
| Typical dose | No validated or approved blend protocol exists. Investigational/vendor ranges for the components: retatrutide titrated from ~2 mg up toward 8–12 mg once weekly subcutaneous in trials; cagrilintide ~0.3–2.4 mg once weekly subcutaneous. Research use only — doses are not clinically established for the mixture. |
|---|---|
| Half-life | Component-dependent and not characterized for the mixture. Both retatrutide and cagrilintide are engineered for once-weekly dosing, consistent with multi-day plasma half-lives. |
Safety
Not FDA-approved in any form; sold as a research/grey-market compound while both components remain investigational. No combination-specific human safety data. Known incretin- and amylin-class risks include nausea, vomiting and other GI effects, with retatrutide's glucagon agonism raising additional questions around heart rate and glucose handling under ongoing study. Stacking two appetite-suppressing agents may amplify GI and nutritional risks.
Vendors selling Retatrutide + Cagrilintide
No vendor listings on file yet.
Research
Obesity is increasingly managed with medications as disease-modifying therapies, reflecting its role as a gateway disease driving metabolic, cardiovascular, reproductive, neuropsychiatric, and mechanical conditions.
source →Obesity, a multifaceted and chronic condition characterized by excessive fat accumulation, poses significant risks to overall health and is associated with various metabolic and cardiovascular complications.
source →Obesity is a complex, multifactorial disease and a growing global health challenge associated with type 2 diabetes, cardiovascular disorders, cancer, and reduced quality of life.
source →Introduction Obesity is the modern world's current epidemic, with substantial health and economic impact. This study aimed to provide a narrative overview of the past, currently available, and future treatment options that offer therapeutic and preventive advantages for obesity management.
source →The association between anti-obesity medications (AOMs) as well as their weight-loss effects and cardiovascular outcomes need to be comprehensively investigated.
source →